Latest:
Dr. Falkson on the Use of Sacituzumab Govitecan in HR+/HER2- Breast Cancer
Carla Falkson, MD, MBChB, MMed, discusses the use of the antibody-drug conjugate sacituzumab govitecan-hziy in hormone receptor–positive, HER2-negative breast cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Ryan McDonald
Latest:
Frontline Ibrutinib/Venetoclax Elicits Responses in Waldenström Macroglobulinemia, But Has Safety Concerns
The combination of ibrutinib and venetoclax produced rapid and deep responses in previously untreated patients with Waldenström macroglobulinemia but there was a higher-than-anticipated rate of ventricular arrhythmia that prompted stopping treatment.
Han Cun, MD
Latest:
Grief and Oncology: Lessons From a Trainee
Although grief never leaves us, we learn how to cope. And as we become seasoned oncologists, I hope we can not only empathize with our patients, but learn to manage this storm of emotions, so that ultimately, we can touch so many more lives in the future.
Thomas Bauer, MD
Thomas Bauer, MD, is the chair of surgery at Jersey Shore University Medical Center and Hackensack Meridian Health School of Medicine
Latest:
Early Detection, Surgical Innovation, and Multidisciplinary Collaboration Evolve Lung Cancer Care: With Ziad Hanhan, MD, Thomas Bauer, MD, and Rachel NeMoyer, MD
Drs Hanhan, Bauer, and NeMoyer discuss the ins and outs of lung cancer diagnosis, surgical management, and evolving treatment paradigms.
Afshin Dowlati, MD
Latest:
Key Takeaways and Future Directions for Managing Brain Metastases in SCLC
Dr. Dowlati concludes by affirming that the IDeate-Lung01 trial was thoughtfully designed and executed, incorporating critical assessment of brain metastases to evaluate intracranial efficacy. He summarizes that ifinatamab deruxtecan achieved high, rapid, and durable intracranial response rates comparable to systemic outcomes, with strong disease control and no additional toxicity in patients with baseline brain metastases. These findings support I-DXd as a promising therapy for patients with extensive-stage small cell lung cancer, including those with CNS involvement. Dr. Dowlati reflects on the broader implications of these results, suggesting that as systemic agents with significant intracranial activity become available, the traditional role of brain radiation—particularly whole-brain or stereotactic radiotherapy—may need to be reconsidered. He emphasizes that future research should explore whether effective systemic therapies like I-DXd could safely delay or reduce the need for brain-directed radiation in this population.
Christina Mattina
Latest:
Overcoming Hurdles to Biosimilar Uptake
Sanjiv S. Agarwala, MD, explains that biologics have revolutionized the treatment of serious conditions, including cancer, over the past few decades, however, costs are a pressing issue for all providers and biologics are a major culprit.